[{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Translational Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Naptumomab Estafenatox","moa":"Trophoblast glycoprotein","graph1":"Oncology","graph2":"Phase II","graph3":"NeoTX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeoTX Therapeutics \/ Translational Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"NeoTX Therapeutics \/ Translational Drug Development"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Translational Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||Trophoblast glycoprotein","graph1":"Oncology","graph2":"Phase II","graph3":"NeoTX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeoTX Therapeutics \/ Translational Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"NeoTX Therapeutics \/ Translational Drug Development"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Active Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Trophoblast glycoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoTX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeoTX Therapeutics \/ NeoTX Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"NeoTX Therapeutics \/ NeoTX Therapeutics"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody-drug Conjugate","year":"2020","type":"Series C Financing","leadProduct":"Durvalumab","moa":"||Trophoblast glycoprotein","graph1":"Oncology","graph2":"Phase I","graph3":"NeoTX Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"NeoTX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NeoTX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Active Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2020","type":"Licensing Agreement","leadProduct":"Durvalumab","moa":"||Trophoblast glycoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoTX Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Intravenous Injection","sponsorNew":"NeoTX Therapeutics \/ NeoTX Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"NeoTX Therapeutics \/ NeoTX Therapeutics"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Active Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Trophoblast glycoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoTX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeoTX Therapeutics \/ NeoTX Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"NeoTX Therapeutics \/ NeoTX Therapeutics"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Trophoblast glycoprotein","graph1":"Oncology","graph2":"Phase I","graph3":"NeoTX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeoTX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoTX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Naptumomab Estafenatox","moa":"Trophoblast glycoprotein","graph1":"Oncology","graph2":"Phase I","graph3":"NeoTX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeoTX Therapeutics \/ NeoTX Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"NeoTX Therapeutics \/ NeoTX Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by NeoTX Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Lead Product(s) : Naptumomab Estafenatox

                          Therapeutic Area : Oncology

                          Study Phase : Phase I

                          Recipient : Weill Medical College of Cornell University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          June 08, 2023

                          Lead Product(s) : Naptumomab Estafenatox

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Weill Medical College of Cornell University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Naptumomab estafenatox (NAP; ABR-217620) is a recombinant fusion protein consisting of a chimeric staphylococcal enterotoxin A/E (SEA/SEE) superantigen with several additional substitutions that is linked to a Fab moiety recognizing a tumor-associated gl...

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          January 06, 2022

                          Lead Product(s) : Naptumomab Estafenatox,Docetaxel,Obinutuzumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Translational Drug Development

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Naptumomab estafenatox (NAP) is a cell therapy candidate, currently in Phase I. It is in clinical development for advanced solid tumors utilizing its proprietary Tumor Targeted Superantigen platform.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          November 30, 2021

                          Lead Product(s) : Naptumomab Estafenatox,Durvalumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Active Biotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          May 11, 2021

                          Lead Product(s) : Naptumomab Estafenatox

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Translational Drug Development

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The study was amended to also include assessment of pre-treatment with obinutuzumab to assess its effect on anti-drug antibodies (ADAs) to naptumomab.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          May 07, 2021

                          Lead Product(s) : Naptumomab Estafenatox,Durvalumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Active Biotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Naptumomab Estafenatox, the company’s lead TTS molecule, binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          April 19, 2021

                          Lead Product(s) : Naptumomab Estafenatox,Durvalumab

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : In 2016, Active Biotech and NeoTX entered into a partnership for the development and commercialization of naptumomab in cancer indications.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          November 12, 2020

                          Lead Product(s) : Naptumomab Estafenatox,Durvalumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Active Biotech

                          Deal Size : $71.0 million

                          Deal Type : Licensing Agreement

                          blank

                          08

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The company plans to complete the dose escalation phase of the Phase 1b trial of naptumomab estafenatox in combination with durvalumab and continue to develop our patented STR platform.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          February 19, 2020

                          Lead Product(s) : Naptumomab Estafenatox,Durvalumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : $45.0 million

                          Deal Type : Series C Financing

                          blank

                          09

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          June 12, 2019

                          Lead Product(s) : Naptumomab Estafenatox

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : AstraZeneca

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank